08.26 - Lung Cancer (Nichols) - Questions Flashcards
What percentage of heavy smokers get lung cancer
11%
What percentages of lung cancer do the 3 most common make?
Adeno 40%, Squamous 20%, Small Cell 15%
Location of Adeno, Squamous, and Small Cell
Peripheral, Central, Central
Which is most commonly associated with paraneoplastic?
Small Cell
Which is most associated with post-obstructive pneumonia
Squamous
Which is most associated with hypercalcemia
Squamous
Median age at presenation for all
70
In which types is cough more common
Squamous and Small Cell because central
Small Cell is typically treated by
Chemotherapy, unless limited to chest and mediastinal lymph nodes (add radiation)
__ for EGFR mutation
Erlotinib
Erlotinib
EGFR mutation
Crizotinib
Translocated ALK
Targets translocated ALK
Crizotinib
70% of nonsmokers with lung cancer have
Adenocarcinoma
In Adenocarcinoma, often mutations in ___ in never-smokers and ___ in smokers
EGFR-dependent pathway in never-smokers, KRAS-dependent pathway in smokers
KRAS mutations confer resistance to
Erlotinib
Type most likely to be responsive to targeted therapy
Adenocarcinoma
4 Gross Path features of Adeno
Peripheral, Solitary, Infiltrate pleura, Spiculated
Most common micro type of Adeno
Acinar
Adeno types with poor prognosis
Micropapillary, Solid
Adeno types with good prognosis
Lepidic
Treatment for Adenocarcinoma
Surgery if low stage, Targeted (Erlotinib, Crizotinib), Radiation + Double Chemo if inoperable
Adenocarcinomas are more likely to have ___ mutations and almost never have __ mutations
EGFR, KRAS
Adeno in Situ is characterized by
Non-destructive growth along intact alveolar septa (lepidic growth)
2 Types of Adeno In Situ and Pathogenesis
Non-mucinous from terminal respiratory unit cells (EGFR); Mucinous from Bronchiolar Epithelium (KRAS)
Gross Path of Adeno In Situ
Single or Multifocal Nodules, or pneumonia-like consolidation
Micro Path of Adeno In Situ
Replaces alveolar lining
Symptoms and Signs of Adeno In Situ
majority have none
Tx of Adeno In Situ
Surgery; Erlotinib or Crizotinib if applicable; Chemo
Two defining features of Squamous Cell
Keratinization and/or Intracellular Bridges
Pathogenesis of Squamous Cell
Squamous metaplasia of bronchial mucosa
Hypercalcemia
Squamous Cell